Movement Alert｜Novo-Nordisk A/S Rises 3.11% in Regular Trading, Q2 Earnings Beat Expectations with Full-Year Guidance Raised

Market Focus08-05 22:27

On August 5, Novo-Nordisk A/S rose 3.11% in regular trading, trading at 45.655 USD/share, with turnover of 348 million USD.

On the news front, the company reported Q2 adjusted EPS of $0.96, beating the analyst consensus of $0.81 by 18.5%. Revenue came in at $12.209 billion, surpassing the $11.35 billion estimate. The company simultaneously raised its full-year sales and operating profit guidance, primarily driven by elevated GLP-1 product sales expectations. CEO noted that oral Wegovy has captured approximately 90% of the oral obesity drug market, with 1.5 million patients currently on the tablet form. The CFO also indicated that cost-saving initiatives targeting 8 billion Danish kroner are ahead of schedule.

The rebound follows a nearly 10% plunge last week after the company's cardiovascular drug candidate ziltivekimab failed to meet its primary endpoint in a Phase 3 trial, and reflects market re-pricing of the core GLP-1 franchise's resilience.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1197719454?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 22:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197719454","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Novo-Nordisk A/S Rises 3.11% in Regular Trading, Q2 Earnings Beat Expectations with Full-Year Guidance Raised","media":"Market Focus","content":"<p><p>On August 5, Novo-Nordisk A/S rose 3.11% in regular trading, trading at 45.655 USD/share, with turnover of 348 million USD.</p><p>On the news front, the company reported Q2 adjusted EPS of $0.96, beating the analyst consensus of $0.81 by 18.5%. Revenue came in at $12.209 billion, surpassing the $11.35 billion estimate. The company simultaneously raised its full-year sales and operating profit guidance, primarily driven by elevated GLP-1 product sales expectations. CEO noted that oral Wegovy has captured approximately 90% of the oral obesity drug market, with 1.5 million patients currently on the tablet form. The CFO also indicated that cost-saving initiatives targeting 8 billion Danish kroner are ahead of schedule.</p><p>The rebound follows a nearly 10% plunge last week after the company's cardiovascular drug candidate ziltivekimab failed to meet its primary endpoint in a Phase 3 trial, and reflects market re-pricing of the core GLP-1 franchise's resilience.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Novo-Nordisk A/S Rises 3.11% in Regular Trading, Q2 Earnings Beat Expectations with Full-Year Guidance Raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Novo-Nordisk A/S Rises 3.11% in Regular Trading, Q2 Earnings Beat Expectations with Full-Year Guidance Raised\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-05 22:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 5, Novo-Nordisk A/S rose 3.11% in regular trading, trading at 45.655 USD/share, with turnover of 348 million USD.</p><p>On the news front, the company reported Q2 adjusted EPS of $0.96, beating the analyst consensus of $0.81 by 18.5%. Revenue came in at $12.209 billion, surpassing the $11.35 billion estimate. The company simultaneously raised its full-year sales and operating profit guidance, primarily driven by elevated GLP-1 product sales expectations. CEO noted that oral Wegovy has captured approximately 90% of the oral obesity drug market, with 1.5 million patients currently on the tablet form. The CFO also indicated that cost-saving initiatives targeting 8 billion Danish kroner are ahead of schedule.</p><p>The rebound follows a nearly 10% plunge last week after the company's cardiovascular drug candidate ziltivekimab failed to meet its primary endpoint in a Phase 3 trial, and reflects market re-pricing of the core GLP-1 franchise's resilience.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"","article_id":"1197719454","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197719454","pubTimestamp":1785940074,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 5, Novo-Nordisk A/S rose 3.11% in regular trading, trading at 45.655 USD/share, with turnover of 348 million USD.On the news front, the company reported Q2 adjusted EPS of $0.96, beating...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"走势警报|诺和诺德A/S常规交易上涨3.11%，第二季度盈利超出预期，全年指引上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"On August 5, Novo-Nordisk A/S rose 3.11% in regular trading, trading at 45.655 USD/share, with turnover of 348 million USD.On the news front, the company reported Q2 adjusted EPS of $0.96, beating the analyst consensus of $0.81 by 18.5%. Revenue came in at $12.209 billion, surpassing the $11.35 billion estimate. The company simultaneously raised its full-year sales and operating profit guidance, primarily driven by elevated GLP-1 product sales expectations. CEO noted that oral Wegovy has captured approximately 90% of the oral obesity drug market, with 1.5 million patients currently on the tablet form. The CFO also indicated that cost-saving initiatives targeting 8 billion Danish kroner are ahead of schedule.The rebound follows a nearly 10% plunge last week after the company's cardiovascular drug candidate ziltivekimab failed to meet its primary endpoint in a Phase 3 trial, and reflects market re-pricing of the core GLP-1 franchise's resilience.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1197719454","isCrawlerRequest":true}